Global /United States /Technology /Software - Application /ACON
chevron_leftBack
Aclarion, Inc. logo

Aclarion, Inc.

ACON
NASDAQ: ACON Delayed
3.25USD -3.6%
As of 13 June 2026, Aclarion, Inc. has a market cap of $7.42M USD, ranking #42786 globally and #5477 in the United States. It ranks #6472 in the Technology sector, and #2126 in the Software - Application industry.
Global Rank
42786
Country Rank
5477
Sector Rank
6472
Industry Rank
2126
Key Stats
Market Cap
$7.42MUSD
Enterprise Value
-$4.33MUSD
Revenue (TTM)
$75.73KUSD
EBITDA (TTM)
-$6.82MUSD
Net Income (TTM)
-$7.24MUSD
PS Ratio
101.6
PB Ratio
0.2
Company Profile
Country (HQ)
Sector
Technology
Industry
Software - Application
CEO
Brent Ness open_in_new
Employees
6
Founded
2008
IPO
22 Apr 2022
Website
aclarion.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-3.6% -13% 6.2% -12% -58% -53%

News

Loading...

ACON Analyst Forecasts

Loading...

Markets

Exchange Ticker Price
NASDAQ
MIC: XNAS
PRIMARY
ACON
Aclarion Inc Ordinary Shares
ISIN: US6551874091
Shares Out.:
2.462M1 Shares Float: 1.363M2
TV:
SA:
YF:
GF:
NQ:
BA:
MS:
3.25 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Aclarion, Inc.

Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

Similar Companies

Industry: Software - Application (United States)
Name
Market Cap diff.
PE
GOOG
$4.23T
57M%
32.0
MSFT
$3.15T
43M%
26.6
META
$1.7T
23M%
28.5
ORCL
$471.18B
6M%
29.4
NFLX
$387.9B
5M%
29.8
$330.74B
4M%
224.1
Industry: Software - Application (Global)
Name
Market Cap diff.
PE
$551.54B
4.32T HKD
7M%
17.8
SAP
$200.91B
173.83B EUR
3M%
23.9
PRX
$109.47B
94.71B EUR
1M%
6.3
$91.21B
1M%
29.2
NTES
$71.25B
960K%
14.8
3690
$65.51B
513.4B HKD
883K%
-
chevron_leftBack